Research guide / Tesamorelin

What is Tesamorelin? A Complete Research Guide.

Updated August 2026 · 10 minute read

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) and one of the few peptides in this hub with a full FDA approval behind it — for a specific, narrow indication. This guide separates what the trials showed from what the label actually says.

Research information only. This article summarises published research and regulatory documents. It is not medical advice, a dosing guide, or a recommendation to use any product. Trial findings in HIV-associated lipodystrophy do not predict outcomes in any other population.

01 / Overview

What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), modified with a hexenoyl group at the N-terminus to extend its half-life. It stimulates the pituitary to release growth hormone in a pulsatile pattern, which in turn raises IGF-I.[5], [6]

It is the active ingredient in Egrifta, which the U.S. FDA approved on November 10, 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The label is explicit about its limits: it is not indicated for weight loss (the effect is weight-neutral), and long-term cardiovascular benefit and safety have not been studied.[6]

That makes tesamorelin unusual among the peptides in this hub: it has a completed Phase 3 programme and a genuine regulatory approval — but for one specific condition in one specific population. Everything below should be read with that boundary in view.

View the tesamorelin research listing

02 / Mechanism

How does tesamorelin work?

Tesamorelin mimics endogenous GHRH, binding GHRH receptors on pituitary somatotrophs to stimulate growth hormone release. Growth hormone then acts on the liver and other tissues to raise IGF-I, and has direct lipolytic effects — particularly on visceral adipose tissue.[1], [6]

Step	What happens	Evidence context
GHRH receptor binding	Tesamorelin binds pituitary GHRH receptors, stimulating pulsatile growth hormone release.	Established pharmacology; basis of the approved indication.
IGF-I elevation	Growth hormone raises IGF-I; the pivotal trial measured an 81.0% increase.	Expected on-target effect; the label requires IGF-I monitoring.
Visceral lipolysis	Growth hormone activity preferentially reduces visceral adipose tissue; VAT fell 15.2% vs a 5.0% rise on placebo.	Demonstrated in Phase 3 trials in HIV lipodystrophy only.

The FDA label requires regular IGF-I monitoring and advises considering discontinuation in patients with persistent elevations. A mechanism that raises growth hormone and IGF-I is also why the label carries warnings about neoplasms, fluid retention, and glucose intolerance.

03 / Published evidence

Peer-reviewed findings

The pivotal Phase 3 trial (Falutz et al., NEJM 2007) randomised 412 HIV-infected patients with abdominal fat accumulation to tesamorelin 2 mg or placebo daily for 26 weeks. Visceral adipose tissue decreased by 15.2% on tesamorelin and increased by 5.0% on placebo; triglycerides fell by 50 mg/dL versus a 9 mg/dL rise; IGF-I rose by 81.0%. Glycaemic measures did not differ significantly, though more tesamorelin patients withdrew due to adverse events.[1]

A 2010 pooled analysis of both Phase 3 trials plus safety-extension data (806 patients randomised 2:1) confirmed the visceral-fat reduction at week 26 and reported that fat reaccumulated when treatment was switched to placebo — supporting an on-treatment effect rather than a durable change.[2]

A 2014 JAMA trial (Stanley et al., 50 patients, 6 months) extended the picture to liver fat: tesamorelin reduced visceral adipose tissue (treatment effect −42 cm²) and reduced liver fat (net treatment effect −2.9% in lipid-to-water percentage). Fasting glucose rose modestly at 2 weeks but not at 6 months.[3]

Read together, the peer-reviewed record shows a consistent, reproducible reduction in visceral fat in ART-treated HIV patients with lipodystrophy. The evidence base does not extend to general weight management, and the label states the product is not indicated for weight loss.[1], [2]

04 / Trial records

Registered clinical trials

Unlike most peptides in this hub, tesamorelin has a completed, registry-documented Phase 3 programme. Key records below; enrolment figures are as recorded in the registry.

Trial	Registry / publication	Enrolment	Design	Headline result
Pivotal Phase 3	NCT00123253 · NEJM 2007	412	26-week, double-blind, placebo-controlled	VAT −15.2% vs +5.0% placebo
Phase 3 extension	NCT00608023	263	26-week safety extension	Confirmed first Phase 3 observations
Pooled analysis	JCEM 2010 (PMID 20554713)	806	Two Phase 3 trials + extension	VAT reduction maintained on treatment; reaccumulated off treatment
Liver-fat trial	JAMA 2014	50	6-month, double-blind, placebo-controlled	VAT −42 cm²; liver fat −2.9% net effect

Registry data from ClinicalTrials.gov as recorded for this August 2026 update. The extension study enrolled completers of the earlier TH9507 study.[4]

Afiya Labs lists a tesamorelin reference material for laboratory research. The catalogue entry is not a medicine listing and is not presented as suitable for human use.

See the tesamorelin catalogue entry

Shop Tesamorelin pen

05 / Safety evidence

What safety evidence exists?

In the pivotal trial, adverse events did not differ significantly between tesamorelin and placebo overall, but more patients in the tesamorelin group withdrew because of an adverse event. IGF-I rose by 81.0% on treatment — an expected pharmacological effect that requires monitoring.[1]

The FDA label lists contraindications including disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity, and pregnancy. Warnings and precautions cover neoplasms, elevated IGF-I, fluid retention (including oedema, arthralgia, and carpal tunnel syndrome), and glucose intolerance.[6]

The label also states that long-term cardiovascular safety has not been studied. That limitation remains part of the official prescribing information and should frame any reading of the trial data.[6]

06 / Regulators

Status in the US, Europe, and UAE

United States

Tesamorelin (Egrifta) is FDA-approved since November 10, 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The approval is narrow: the label states it is not indicated for weight loss, that long-term cardiovascular benefit and safety have not been studied, and that it does not improve adherence to antiretroviral therapy.[5], [6]

European Union

Tesamorelin does not hold an EU marketing authorisation as a medicine. The clinical evidence cited in this guide comes from the US development programme and investigator-led trials.[1]

United Arab Emirates

The Emirates Drug Establishment maintains the UAE's public registered medical product directory. We did not rely on a directory search to infer approval, non-approval, legality, availability, or permission for use of any specific product; those questions require confirmation from the EDE. Approved medicines in the UAE are dispensed through licensed channels.[7]

07 / Quick answers

Frequently asked questions

Is tesamorelin an approved medicine?

Yes — in the United States, for one specific indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (Egrifta, approved November 10, 2010). The approval does not extend to weight loss or general use.

Is tesamorelin a weight-loss drug?

No. The FDA label explicitly states it is not indicated for weight loss management and describes its effect as weight-neutral. Its measured effect is on visceral fat distribution in a specific patient population.

What did the main trial show?

In 412 HIV patients with abdominal fat accumulation, 26 weeks of tesamorelin 2 mg daily reduced visceral adipose tissue by 15.2% versus a 5.0% increase on placebo, with improved triglycerides. IGF-I rose 81.0%, and more tesamorelin patients withdrew due to adverse events.

Does the fat stay off after stopping?

The pooled Phase 3 analysis found that visceral fat reaccumulated when patients were switched from tesamorelin to placebo, indicating the effect depends on continued treatment.

What are the main safety warnings?

The label lists contraindications for pituitary-axis disruption, active malignancy, hypersensitivity, and pregnancy, and warnings for elevated IGF-I, fluid retention (oedema, arthralgia, carpal tunnel), and glucose intolerance. Long-term cardiovascular safety has not been studied.

What does the UAE directory show?

It is a public register of medical products. This guide does not turn a directory search result — or the absence of one — into a claim about approval, legality, or permitted use. The EDE is the appropriate authority for a current determination.

08 / Sources